OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma (Nasdaq: OKYO) reported that Chief Scientific Officer Raj Patil, PhD, has increased his personal stake in the company by purchasing 3,363 ordinary shares on Nasdaq at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO) reported that Chief Scientific Officer Raj Patil, PhD, has increased his personal stake in the company by purchasing 3,363 ordinary shares on Nasdaq at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

OKYO Pharma is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to the company, it plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

Market Context

Historical insider-purchase announcements split between -2.63% and 5.56%, adding a mixed precedent t...

Analysis

Historical insider-purchase announcements split between -2.63% and 5.56%, adding a mixed precedent to this disclosure. The active F-3 shelf, registered for up to $200,000,000, was a financing risk to monitor.

Key Figures

Shares purchased: 3,363 ordinary shares Purchase price: $1.49 per share Total holding: 20,030 ordinary shares +3 more

Shares purchased

3,363 ordinary shares

Chief Scientific Officer purchase

Purchase price

$1.49 per share

NASDAQ transaction

Total holding

20,030 ordinary shares

Chief Scientific Officer holding after purchase

Trial phase

Phase 3

Global pivotal clinical trial

Trial timing

Second half of this year

Planned global pivotal clinical trial initiation

Planned enrollment

Approximately 111 patients

Phase 3 urcosimod trial for neuropathic corneal pain

Historical Context

5 past events · Latest: Jul 23

5 events

1. Jul 23

   Insider purchase

   24h Move

   -2.6%

   Director purchased 5,000 ordinary shares at $1.48 per share

2. Jul 23

   Insider purchase

   24h Move

   -2.6%

   Chief executive officer purchased 15,000 ordinary shares

3. Jul 22

   Insider purchase

   24h Move

   +5.6%

   Chief development officer purchased 3,500 ordinary shares

4. Jul 22

   Insider purchase

   24h Move

   +5.6%

   Chief medical officer purchased 20,000 ordinary shares

5. Jul 21

   Conference presentation

   24h Move

   +5.1%

   Company scheduled presentation at ophthalmology conference on July 22

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuropathic corneal pain, phase 3 pivotal clinical trial

2 terms

neuropathic corneal pain medical

"therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

phase 3 pivotal clinical trial technical

"initiate a global Phase 3 pivotal clinical trial"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did OKYO Pharma (OKYO) announce on July 28, 2026?

OKYO Pharma announced that Chief Scientific Officer Raj Patil purchased 3,363 ordinary shares on Nasdaq at $1.49 per share. According to OKYO Pharma, this transaction increased his total holding to 20,030 ordinary shares, signaling a higher personal ownership stake in the company.

How many OKYO Pharma (OKYO) shares does Chief Scientific Officer Raj Patil now own?

After his latest purchase, Raj Patil holds 20,030 ordinary shares of OKYO Pharma. According to OKYO Pharma, he acquired an additional 3,363 shares on Nasdaq at $1.49 per share, increasing his overall shareholding in the clinical-stage biopharmaceutical company.

At what price were the new OKYO Pharma (OKYO) shares bought by the Chief Scientific Officer?

The newly acquired OKYO Pharma shares were purchased at $1.49 per share on Nasdaq. According to OKYO Pharma, Chief Scientific Officer Raj Patil bought 3,363 ordinary shares, raising his total ownership to 20,030 shares following this insider share transaction.

What clinical focus does OKYO Pharma (OKYO) have in 2026?

OKYO Pharma focuses on investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to OKYO Pharma, the company is clinical-stage and is developing drug candidates such as urcosimod aimed at addressing these serious ophthalmic conditions.

What Phase 3 trial does OKYO Pharma (OKYO) plan to start for neuropathic corneal pain?

OKYO Pharma plans to start a global Phase 3 pivotal trial for neuropathic corneal pain in the second half of this year. According to OKYO Pharma, the study will enroll about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

How many patients will be enrolled in the planned OKYO Pharma (OKYO) Phase 3 NCP trial?

The planned Phase 3 NCP trial will enroll approximately 111 patients globally. According to OKYO Pharma, this pivotal study will evaluate a single-dose regimen of urcosimod for the treatment of neuropathic corneal pain in a clinical-stage development program.